Financial reports
10-Q
2024 Q3
Quarterly report
13 Feb 24
10-Q
2024 Q2
Quarterly report
9 Nov 23
10-Q
2024 Q1
Quarterly report
10 Aug 23
10-K
2023 FY
Annual report
28 Jun 23
10-Q
2022 Q3
Quarterly report
7 Feb 23
10-Q
2022 Q2
Quarterly report
10 Nov 22
10-Q
2022 Q1
Quarterly report
11 Aug 22
10-K
2022 FY
Annual report
23 Jun 22
10-Q
2022 Q3
Quarterly report
10 Feb 22
10-Q
2022 Q2
Quarterly report
10 Nov 21
Current reports
8-K
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder following Positive Results of PALISADE-2
1 Apr 24
8-K
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
13 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
3 Jan 24
8-K
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
9 Nov 23
8-K/A
Other Events
6 Nov 23
8-K
Other Events
6 Nov 23
8-K
Departure of Directors or Certain Officers
26 Oct 23
8-K
Entry into a Material Definitive Agreement
4 Oct 23
8-K
Other Events
2 Oct 23
Registration and prospectus
S-3
Shelf registration
13 Feb 24
424B5
Prospectus supplement for primary offering
3 Oct 23
424B5
Prospectus supplement for primary offering
8 Aug 23
424B5
Prospectus supplement for primary offering
30 Jun 23
S-3/A
Shelf registration (amended)
17 Mar 23
S-3
Shelf registration
2 Mar 23
D
$2.80 mm in equity, 129 investors
17 Feb 23
S-8
Registration of securities for employees
24 Sep 21
424B5
Prospectus supplement for primary offering
14 May 21
S-3
Shelf registration
15 Mar 21
Proxies
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Jul 23
DEF 14A
Definitive proxy
28 Jul 23
DEFA14A
Additional proxy soliciting materials
6 Oct 22
DEFA14A
Additional proxy soliciting materials
31 Aug 22
DEF 14A
Definitive proxy
31 Aug 22
PRE 14A
Preliminary proxy
19 Aug 22
DEFA14A
Additional proxy soliciting materials
29 Jul 21
DEF 14A
Definitive proxy
29 Jul 21
Other
EFFECT
Notice of effectiveness
1 Mar 24
EFFECT
Notice of effectiveness
22 Mar 23
CORRESP
Correspondence with SEC
17 Mar 23
UPLOAD
Letter from SEC
9 Mar 23
CT ORDER
Confidential treatment order
16 Nov 21
EFFECT
Notice of effectiveness
29 Mar 21
CORRESP
Correspondence with SEC
23 Mar 21
UPLOAD
Letter from SEC
22 Mar 21
EFFECT
Notice of effectiveness
14 May 20
CORRESP
Correspondence with SEC
8 May 20
Ownership
4
Mary L. Rotunno
6 Mar 24
4
JERRY B GIN
6 Mar 24
4
Margaret M FitzPatrick
6 Mar 24
4
Joanne Curley
6 Mar 24
4
Ann Michelle Cunningham
6 Mar 24
4
JON S SAXE
6 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24